Biomarkers of EPS: Can we go ''back to the future''?

Peritoneal Dialysis International

Volumn 30, Issue 2, 2010, Pages 158-160

  Summers, Angela M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; INTERLEUKIN 6; POTASSIUM ION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ARTICLE; DIALYSIS MEMBRANE; EARLY DIAGNOSIS; HEMODIALYSIS PATIENT; HUMAN; INTESTINE OBSTRUCTION; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; PERITONEAL FIBROSIS;

EID: 77957584070     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2009.00267     Document Type: Article

References (13)

1. Kawanishi H. The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis. Int J Artif Organs 2005; 28:150-155.
2. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88: S43-S49.
3. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S19-S29.
4. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-1936.
5. Liu L, Shi CX, Ghayur A, Zhang C, Su JY, Hoff CM, et al. Prolonged peritoneal gene expression using a helperdependent adenovirus. Perit Dial Int 2009; 29:508-516.
6. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541.
7. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S48-S56.
8. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-291.
9. Summers AM. Encapsulating peritoneal sclerosis-have we found the perpetrator? Perit Dial Int 2009; 29:499-501.
10. Sampimon DE, Korte MR, Lopes Barreto D, Vlijm A, de Waart R, Struijk DG, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2010; 30:163-169.
11. Topley N, Michael D, Bowen T. CA125: holy grail or a poisoned chalice. Nephron Clin Pract 2005; 100:c52-c54.
12. Gillerot G, Goffin E, Michel C, Evenepoel P, van Biesen W, Tintillier M, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67:2477-2487.
13. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009; 111: c149-c154.